TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker
stability and the primacy of payload delivery
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
